Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5940
    +0.0004 (+0.06%)
     

  • NZD/EUR

    0.5546
    +0.0000 (+0.00%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.84
    +0.03 (+0.04%)
     

  • GOLD

    2,324.30
    -14.10 (-0.60%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,293.21
    +91.94 (+0.53%)
     

  • NIKKEI 225

    37,715.25
    -744.83 (-1.94%)
     

  • NZD/JPY

    92.3090
    +0.1940 (+0.21%)
     

Why Sanofi May Be a Frontrunner in Endemic COVID-19

Natalie Forbes, The Motley Fool
·4-min read
Why Sanofi May Be a Frontrunner in Endemic COVID-19

Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.

Continue reading